



IFW 4

PATENT

Attorney Docket No. 06267.0130-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
**Leena OTSOMAA et al.** ) Group Art Unit: 1625  
)  
Application No.: 10/541,677 ) Examiner: Binta M. ROBINSON  
)  
Filed: October 28, 2005 ) Confirmation No.: 8394  
)  
For: PYRIDINE DERIVATIVES USEFUL )  
FOR INHIBITING )  
SODIUM/CALCIUM EXCHANGE )  
SYSTEM )  
)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

The documents listed were cited or submitted in copending application no. 10/482,396.

Copies of the listed foreign and non-patent literature documents are attached.  
Copies of the U.S. patent publications are not enclosed.

05/24/2007 YPOLITE1 00000082 10541677

01 FC:1806

186

Applicants respectfully request that the Examiner consider the listed document and indicate that it was considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed document is material or constitutes "prior art." If the Examiner applies the document as prior art against any claim in the application and Applicants determine that the cited document does not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed document, should the document be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: May 23, 2007

By:   
Jill K. MacAlpine  
Limited Rec. No. L0213



IDS Form PTO/SB/08: Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/541,677
				Filing Date	October 28, 2005
				First Named Inventor	Leena OTSOMAA
				Art Unit	1625
				Examiner Name	Binta M. ROBINSON
Sheet	1	of	1	Attorney Docket Number	06267.0130-00000

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1	US-3,862,232	01-21-1975	Lednicer	
	2	US-2,820,817	01-21-1958	Sam	
	3	US-5,703,118	12-30-1997	Durand et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	4	GB 1 068 751	05-10-1967	Upjohn Co.		
	5	GB 1 154 119	06-04-1969	Merck Aktiengesellschaft		
	6	WO 00/64445	11-02-2000	Bristol-Myers Squibb Co.		

NONPATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
	7	Noble, D., "Simulation of Na/CA Exchange Activity during Ischemia," <i>Ann. N.Y. Acad. Sci.</i> (2002) 976:431-437.	
	8	Office Action from copending U.S. Application No. 10/482,396 dated February 28, 2007.	
	9	Sipido, K. R. et al. "Altered Na/Ca exchange activity in cardiac hypertrophy and heart failure: a new target for therapy?" <i>Cardiovascular Research</i> (2002), 53:782-805.	
	10	Sipido, K. R. et al., "Sodium Calcium Exchange as a Target for Antiarrhythmic Therapy," <i>Handbook of Experimental Pharmacology</i> , NY: Springer-Verlag (2006) 171:159-199.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.